BCIQ Profiles

Company Profile Report

Upbeat Lilly earnings come with positive psoriasis results, delays for two autoimmune programs

Lilly announced positive Phase III data for autoimmune disease candidate mirikizumab and attributed a bump in revenue, adjusted guidance and trial delays to the COVID-19 pandemic.

As part of its 1Q20 earnings, Eli Lilly and Co. (NYSE:LLY) said mirikizumab met the co-primary and key secondary endpoints

Read the full 450 word article

How to gain access

Continue reading with a
two-week free trial.